1 Patients experienced a graded increased risk in incidenc
2 Patients experienced a mean of 8.2 AEs; the most frequen
3 Patients experienced fever, skin rash, arthralgia and co
4 Patients experienced more days alive and free of deliriu
5 Patients experienced more frequent thrombocytopenia in t
6 Patients experienced the greatest average change in BMD
7 ow-up of 68 months, 5-year DSS was 86% and
1 patient experienced a local recurrence.
8 months after dislocation of the PCIOL, and
1 patient experienced iris capture of the PCIOL after surg
9 R 12 weeks after end of treatment, whereas
1 patient experienced relapse at week 4 following treatmen
10 In total,
104 patients experienced MACE (median time to event, 36 week
11 a median follow-up of 49.5 months, 5 of
107 patients experienced a local relapse within a median of
12 follow-up period of 28 months, 52 of the
115 patients experienced a relapse; the 1-year relapse rate
13 rs (interquartile range, 1.5-3.9 years),
115 patients experienced the primary composite outcome of ca
14 All
12 patients experienced at least one adverse event during t
15 through or nonresponse were not observed;
12 patients experienced a partial response.
16 009, were included in the control group (
123 patients experienced 183 cardiopulmonary arrests) and be
17 ysis (mean follow-up of 52+/-22 months),
125 patients experienced 136 hard events (18 cardiac deaths
18 A total of
129 patients experienced at least 1 treatment-related advers
19 Finally, 47 of
131 patients experienced kidney dysfunction during the media
20 During a median follow-up of 19 months,
14 patients experienced BSI (9.5%; 95% confidence interval,
21 In the entecavir cohort, 2 (1.37%) of
145 patients experienced HBV recurrence, none of which had e
22 Overall, 144 (97%) of
149 patients experienced treatment-related adverse events, w
23 After stopping therapy, 13 of
15 patients experienced a virological relapse.
24 While 3 of
15 patients experienced only transient benefit after 4 week
25 In total, 47 of
152 patients experienced HFS (30.9%), 39.5% with the new oin
26 Twenty-six (
17%)
patients experienced 5-day failure; SOFA, source of UGIB
27 ne adverse event during treatment: two (
17%)
patients experienced anaemia, eight (67%) neutropenia, a
28 subclinical THV thrombosis, whereas 5 (
18%)
patients experienced clinically overt obstructive THV th
29 A total of 581 (
19%)
patients experienced moderate, severe, or life-threateni
30 A total of 11
196 patients experienced HO-GNR bacteremia during the study
31 During the study,
2 patients experienced viral breakthrough and 1 patient re
32 702 (12.
2%)
patients experienced an LASDelta >5.
33 Three hundred eighty (32.
2%)
patients experienced intrahospital cardiovascular events
34 85 composite visceral transplants, 15 (5.
2%)
patients experienced vascular complications.
35 Seventy (9.
2%)
patients experienced major neurologic complications with
36 In this study, about 1 in
20 patients experienced a critical illness resulting in ICU
37 3.2) months; 12 (52.2%) and 14 (60.9%) of
23 patients experienced SEGA volume reductions of >/=50% an
38 Within 18 months after randomization
23 patients experienced a rejection episode: MMF/pred (27.0
39 At a median follow-up of 2.9 years,
244 patients experienced the primary outcome.
40 er 514 395 person-years of follow-up, 76
252 patients experienced incident AF for a crude AF incidenc
41 Using the ICE,
253 patients experienced a response and 275 did not.
42 28 patients experienced 40 serious adverse events; eight of
43 Only
28 patients experienced a second relapse.
44 imab plus pemetrexed group (119 [41%] of
292 patients) experienced at least one serious adverse event
45 Nevertheless,
3 patients experienced significant disease sequelae and 4
46 Eighty-five (13.
3%)
patients experienced BPAR.
47 Within 30 days of TAVR, 87 (3.
3%)
patients experienced a stroke (TF 58 [3.8%]; TA 29 [2.7%
48 Thirty-seven of the 445 (8.
3%)
patients experienced a cerebral abscess at a median age
49 I], 26 [range, 23-31]) were included, and
30 patients experienced a cardiovascular event during a med
50 (range, 0.1 to 10.1 years), during which
30 patients experienced an ACE.
51 Overall, 18 of
31 patients experienced malignant transformation; of these,
52 Twenty-three of
31 patients experienced tumor progression (median progressi
53 ents underwent liver transplantation, and
35 patients experienced one or more liver-related events.
54 f 229 (interquartile range, 116-305) days,
4 patients experienced 21 episodes, with correct detection
55 During maintenance therapy,
4 patients experienced reactivation in risk organs.
56 Forty-eight (20.
4%)
patients experienced ulcer rebleeding and 46 (19.6%) dev
57 were normotensive at first presentation,
40 patients experienced hypotension during their ED stay.
58 During a mean follow-up of 7 years, 86 (
40%)
patients experienced the arrhythmic outcome.
59 Thirteen of 58 (22.
41%)
patients experienced some kind of complication in the re
60 atal myocardial infarction, and stroke),
410 patients experienced cardiac events, and 561 patients di
61 A total of 11
424 patients experienced RD after cataract surgery, with an
62 were included in the intervention group (
46 patients experienced 65 cardiopulmonary arrests).
63 After drug therapy discontinuation,
5 patients experienced outer retinal regeneration (3 subfo
64 n follow-up of 41 (28-56) months, 19 (27.
5%)
patients experienced arrhythmic events, such as sudden d
65 Overall, 79 (9.
5%)
patients experienced HAT, E-HAT was diagnosed in 23, and
66 Within 30 days, 13 (0.
50%)
patients experienced a TIA (TF 10 [0.67%]; TA 3 [0.27%];
67 d tacrolimus monotherapy.Fifteen (29%) of
52 patients experienced antibody-mediated rejection (AMR),
68 ine transthoracic echocardiography, 37 (
53%)
patients experienced MACE during a median follow-up peri
69 The remaining
55 patients experienced CMV-IRR; 35 of those developed CMV-
70 In phase 2, eight (14%) of
59 patients experienced 12 grade 3 or higher adverse events
71 primarily nontreated aortic segments (5 of
6 patients experienced type B dissection during follow-up)
72 a median 3.8 years of follow-up, 219 (22.
6%)
patients experienced the primary outcome (136 CV events
73 A total of 9566 (9.
6%)
patients experienced a major bleeding event during hospi
74 27 (45%) of
60 patients experienced a serious adverse event.
75 ition to standard of care until at least
691 patients experienced an adjudicated event included in th
76 Ten eyes (18%) from
7 patients experienced a new episode of vision loss during
77 surgery in 2010 and 2011 revealed that 66.
7%
patients experienced hyperglycemia.
78 In the TEP group, 39 (20.
7%)
patients experienced pain, compared with 62 (33.2%) pati
79 A total of
79 patients experienced SSIs within 30 days of surgery, 27
80 ed wound healing, were seen in 6 patients;
8 patients experienced severe pain.
81 Eighty-eight (25.
8%)
patients experienced an asthma exacerbation in the prior
82 163 patients randomized to cryoablation,
84 patients experienced ERAF (51.5%).
83 Thirty-three (
87%)
patients experienced adverse events.
84 respiratory tract infection, and headache;
9 patients experienced serious adverse events, all of whic
85 ycardia, tachycardia, and asystole); 22 (
9%)
patients experienced 38 nonserious adverse events report
86 llow-up of a mean of 4.1 years, 2183 (23.
9%)
patients experienced a major adverse cardiac event.
87 Three (
9%)
patients experienced five serious treatment-related adve
88 Overall,
914 patients experienced a decline in eGFR >20% in the first
89 an follow-up period of 2.6 +/- 1.0 years,
93 patients experienced the primary endpoint.
90 rquartile range [IQR]: 2.3 to 7.3 years),
98 patients experienced a MACE.
91 mPC, i.e., ranibizumab was administered if
a patient experienced a best-corrected visual acuity [BCVA
92 In total, 19,520 (20.0%)
ACS patients experienced depression within 2 years after the
93 Additional patients experienced procedural major adverse events rel
94 Fifteen
additional patients experienced at least one major complication.
95 Additionally,
patients experienced the movements of the virtual legs d
96 ALGS patients experienced a trend toward greater freedom from
97 All patients experienced a favorable response, with a mean t
98 All patients experienced complete response after retreatment
99 All patients experienced diffuse hyperpigmentation.
100 All patients experienced follicular and confluent areas of r
101 All patients experienced immediate reduction in upper- to lo
102 All patients experienced improvement.
103 All patients experienced marked improvement of symptoms with
104 All patients experienced multiple adverse effects, including
105 All patients experienced self-limited symptoms after postexp
106 All patients experienced severe toxicity, with World Health
107 All patients experienced some degree of segmental left ventr
108 All patients experienced thrombocytopenia (41 episodes in 27
109 sm improved with l-DOPA; however, nearly
all patients experienced early motor fluctuations that quick
110 onths of the postdiscontinuation period,
all patients experienced virological and 25 (76%) had bioche
111 Three patients (8.3% of
all patients) experienced 6 systemic reactions (0.15% of dos
112 ow-up of 533 days, 4 of 14 splenectomy-
alone patients experienced graft loss (median=320 days), compa
113 Five non-
anticoagulated patients experienced nonfatal thromboembolic events (1.1
114 s in the CGA arm, compared with standard
arm patients, experienced significantly less all grade toxic
115 (1%, 12-week arm) and three (2%, 8-week
arm)
patients experienced a serious adverse event (all unrela
116 Both patients experienced a prostate-specific antigen decline
117 Both patients experienced deterioration of mental status, res
118 Both patients experienced rebound viremia within 2 weeks of t
119 ALGS, FIC1, and
BSEP patients experienced less severely scored pruritus after
120 A total of 77.6% of
CPR patients experienced a complication; approximately 75.0%
121 Overall
diabetic patients experienced a significantly higher risk of targ
122 Fewer directly
discharged patients experienced a MACE when evaluated with an hsTnT
123 The
DR patients experienced twice the recovery rate of the MT p
124 Each patient experienced 1 symptomatic dengue case and 1 DENV
125 Eight patients experienced grade II-IV acute GVHD, the cumulat
126 Eight patients experienced stable disease > 3 months, includin
127 hs of training with this paradigm, all
eight patients experienced neurological improvements in somati
128 One hundred fifty-
eight patients experienced 204 hypotensive episodes that were
129 Three hundred sixty-
eight patients experienced Enterobacter species bacteremia and
130 Eleven patients experienced a stroke, 5 of those within 4 weeks
131 Twelve of 13
evaluable patients experienced hyperamylasemia higher than grade 2
132 RP2D was established at 400 mg (15
evaluable patients experienced two DLTs).
133 gued patients and control subjects,
fatigued patients experienced atrophy of the right side of the ac
134 Overall,
few patients experienced significant decline in MMSE score.
135 tion (OR 1.13 [95% CI 0.86-1.48]), but
fewer patients experienced sedation-related adverse events (OR
136 Fifteen patients experienced grade 3 to 4 adverse events; the mo
137 The
first patient experienced a complete LGLL remission that was s
138 Five patients experienced grade 3 treatment-related AEs.
139 Five patients experienced other systemic immune-mediated comp
140 Five patients experienced recurrences, but no metastases or t
141 Five patients experienced stable disease for three to 24 cycl
142 Four patients experienced a size reduction and 2 had no chang
143 Four patients experienced manageable adverse effects.
144 Four patients experienced serious AEs; all were considered un
145 eatment because of an adverse event and
four patients experienced serious adverse events.
146 One in
four patients experienced treatment delay.
147 Subsequently,
four patients experienced progressive disease, seven experien
148 Thirty-
four patients experienced grade >/= 3 hematologic toxicity.
149 , 79.6+/-16.0) mL/min per 1.73 m(2), low-
GFR patients experienced higher risk of death (hazard ratio
150 Although in the iodixanol 270
group patients experienced less heat discomfort (72% vs 86%, r
151 (4F-PCC group) and 71 of 109 (plasma
group)
patients experienced >/=1 adverse event.
152 HVHF patients experienced faster correction of metabolic acid
153 its original size (Group 1, n = 99); and
ii)
patients experienced a significant reduction in size (Gr
154 Transcatheter aortic valve
implantation patients experienced an acute decrease in shear stress a
155 itiation, 15.6% of SBRT versus 12.6% of
IMRT patients experienced GU toxicity (odds ratio [OR], 1.29;
156 In addition, HCV-
infected patients experienced a twofold and a nearly 17-fold high
157 Brain-
injured patients experienced a maturation defect of the ex vivo
158 Intervention patients experienced less anxiety and depression (median
159 Intervention patients experienced more postextubation stridor (7% vs
160 sion analyses demonstrated that
intervention patients experienced significant reductions in weapon ca
161 mitochondrial DNA levels showed that TB-
IRIS patients experienced greater cell death, especially pre-
162 After 10-year
LAR,
patients experienced a significant and clinically releva
163 Medicaid patients experienced the most surgical delays.
164 4 mo, but if therapy was repeated every 2
mo patients experienced additive antitumor effects.
165 However,
more patients experienced sedation-related adverse events (OR
166 Most patients experienced at least one treatment-emergent adv
167 Most patients experienced cytopenia during treatment, but no
168 Most patients experienced transient fevers and the expected h
169 than death." Irrespective of approach,
most patients experienced the DT LVAD decision as a highly em
170 entral pontine and extrapontine
myelinolysis patients experienced higher intraoperative and periopera
171 Furthermore,
NFLG patients experienced less reverse remodeling but the sam
172 Nine patients experienced a >/=50% increase, six experienced
173 Nine patients experienced a total of 13 unexpected grade 3-5
174 Three of
nine patients experienced objective tumor responses (two comp
175 Nineteen patients experienced disease progression while receiving
176 Nineteen patients experienced myelosuppression higher than grade
177 No patient experienced plasma HIV-1 RNA >200 copies/mL duri
178 crease in neurotoxicity was detected, and
no patient experienced grade >/= 4 toxicity, but three pati
179 No patients experienced a serious adverse event.
180 No patients experienced any serious adverse events.
181 No patients experienced C difficile colitis.
182 No patients experienced complete or partial response, but s
183 No patients experienced graft infection, rejection, or tumo
184 No patients experienced hearing decline.
185 No patients experienced organ rejection.
186 No patients experienced pulmonary toxic effects when treate
187 No patients experienced serious adverse events related to t
188 on, one patient (5%) experienced DGF, and
no patients experienced NODAT.
189 Five nonobese and two
obese patients experienced potentially toxic piperacillin plas
190 A total of 14%
of patients experienced minor adverse drug reactions (ADRs)
191 follow-up of 24 months (2-95 months), 21%
of patients experienced adverse effects, with biological-ta
192 In group 1, 46.4%
of patients experienced any type of thrombosis versus 10.4%
193 single/dual-drug ART initially, and 45.4%
of patients experienced at least 1 episode of VF during fol
194 emained stable on all HRQOL scales, 38.5%
of patients experienced detectable decline on one or more s
195 Nearly 5%
of patients experienced major infections.
196 xicities before hWBRT, and 45% (24 of 53)
of patients experienced grade 3 and 4 toxicities attributab
197 Only 18.6%
of patients experienced new or recurrent ischemic events be
198 During T-DM1 treatment, 38.5% and 2.7%
of patients experienced grade 3 and 4 adverse events, respe
199 Throughout follow-up, 70%
of patients experienced rejection, with 52% showing subclin
200 Throughout follow-up, 70%
of patients experienced rejection, with 52% showing subclin
201 or ulcerative colitis (approximately 75%
of patients experienced a relapse within 5 years after ther
202 lar between formulations (in stage 2, 79%
of patients experienced one or more adverse events in each
203 One year after transplantation, 29.8%
of patients experienced impaired fasting glycemia and 13.4%
204 l, among all plug types, approximately 9%
of patients experienced epiphora and 10% required removal b
205 , 1.8% (rituximab) and 17.6% (fingolimod)
of patients experienced a clinical relapse (hazard ratio fo
206 mong the different tests, similar numbers
of patients experienced MACE after an abnormal test result
207 Thirty-nine percent
of patients experienced a readmission within 12 months of a
208 Fifty-nine percent
of patients experienced ES during daytime hours (P<0.001).
209 Twenty-seven percent
of patients experienced hemoptysis.
210 Thirty-one percent
of patients experienced improvement in BiS scores postopera
211 Twelve percent
of patients experienced long-term disease control without r
212 Forty percent
of patients experienced pain reduction and better QOL at da
213 Seventy percent
of patients experienced thoracic FLT; 30% had FLP.
214 loratory analyses to determine if subsets
of patients experienced better outcomes after stent placeme
215 Subsequently, staged CAS-
OHS patients experienced significantly fewer late hazard pha
216 The
oldest patients experienced 42% (95% CI, 31% to 54%) increased
217 One patient experienced a hypersensitivity reaction and deve
218 One patient experienced a paracentesis related complication
219 One patient experienced a partial recurrence 5 months after
220 One patient experienced abdominal cramps and diarrhea necess
221 One patient experienced dose-limiting toxicity at 4 mg; the
222 One patient experienced drug-induced parkinsonism and sudden
223 One patient experienced postoperative elevation in intraocul
224 One patient experienced posttransplant C3 glomerulonephritis
225 al complications were reported, although
one patient experienced exacerbation of pre-existing gait at
226 fter one to three months after LuTX, and
one patient experienced fatal chronic rejection and hemolyti
227 des were observed in three patients, and
one patient experienced vein perforation.
228 was one episode of grade 3 tumor lysis;
one patient experienced renal failure during the first cycle
229 Only
one patient experienced a dose-limiting toxicity-grade 3 tra
230 While
one patient experienced critical illness with multi-organ fa
231 One
other patient experienced cardiac tamponade, leading to termin
232 Extracorporeal membrane
oxygenation patients experienced more clinically significant iatroge
233 after transplantation, and 132 CMV-
positive patients experienced CMV replication after transplantati
234 Most early
PTLD patients experienced graft rejection before PTLD diagnos
235 BOS, but especially
RAS patients, experienced more frequent episodes of increase
236 total health care cost trajectories but
RYGB patients experienced lower total and prescription costs
237 SAVR patients experienced significant right ventricular systo
238 Risk of Mortality score 5.6%), TAVR and
SAVR patients experienced no difference in 1-year rates of de
239 2.7% to 8.4% (P<0.001), whereas late
senior patients experienced only a minor increase (1.5% to 2.0%
240 Six patients experienced an objective response (20%), includ
241 Six patients experienced grade 2 RP, and two patients experi
242 Six patients experienced modified VARC-2 major vascular comp
243 Six patients experienced serious adverse events possibly rel
244 Although
some patients experienced stable disease for 3 months, none h
245 Reduced starting dose
sorafenib patients experienced significantly lower total cumulativ
246 ded given that 1 in 4 previously
symptomatic patients experienced at least 1 subsequent, albeit nonle
247 Many ocular
syphilis patients experienced vision loss; however, most improved
248 Matched TA-
TAVR patients experienced more adverse procedural events, lon
249 Ten patients experienced viral relapse after treatment cessa
250 tients completing both phases confirmed
that patients experienced greater mouth and throat pain reduc
251 The patient experienced an increase in peripheral blood eosi
252 The patient experienced systemic symptoms without mucosal sy
253 In July 2015,
the patient experienced relapse, with painful collapse of L3
254 Additionally,
the patient experienced repeated pulmonary infections with A
255 ginning of mild therapeutic hypothermia,
the patient experienced malignant diffuse coronary artery sp
256 Postoperatively,
the patient experienced an improvement in neurological sympt
257 induced amenorrhea to have occurred when
the patient experienced >/= 2 years of amenorrhea, commencin
258 Over the following year,
the patient experienced rapid cognitive decline with new-ons
259 One-third of
the patients experienced 1-4 meningitis episodes during the
260 32 (78%) of
the patients experienced 20% or greater reduction in the mea
261 None of
the patients experienced a CML progression.
262 and favorable prognoses, almost half of
the patients experienced a posttransplant cancer.
263 urred in 18 patients: 10%, 4%, and 3% of
the patients experienced anemia, thrombocytopenia, and leuko
264 xicity occurred in 18 10%, 4%, and 3% of
the patients experienced anemia, thrombocytopenia, and leuko
265 None of
the patients experienced any radiation-related ocular morbid
266 Eighty-six percent of
the patients experienced at least 1 AE during treatment.
267 Overall, 6% of
the patients experienced complications.
268 Overall, 6% of
the patients experienced complications.
269 None of
the patients experienced further symptomatic bradyarrythmias
270 None of
the patients experienced liver-related death.
271 None of
the patients experienced metastases nor died of iris melanom
272 None of
the patients experienced postoperative surgical site infecti
273 These patients experienced a significantly higher incidence of
274 Half of
these patients experienced chronic pain conditions before ICU
275 ter initially robust engraftment, 3 of
these patients experienced declining donor myeloid chimerism (
276 ete remission after HSCT2, and half of
these patients experienced relapse again.
277 ous second hit events, suggesting that
these patients experienced a 'shower' of second hit mutations
278 During the outcome year,
these patients experienced significantly more severe exacerbat
279 In addition, 2 of
those patients experienced early arterial thromboembolic compl
280 Three patients experienced complications during scleral lens w
281 Three patients experienced dose-limiting toxicities: 1 at 4.0
282 Three patients experienced grade 3 infusion-related reactions,
283 Three patients experienced skin-only grade 1 to 2 acute GVHD.
284 Three patients experienced treatment failure (6%, 95% CI: 1.3%
285 did not meet the ENDA classification:
Three patients experienced anaphylaxis with different NSAIDs,
286 Only
three patients experienced GFNC during the first 24 months; GF
287 Thirty-
three patients experienced peripheral neuropathy, among whom,
288 Twenty-
three patients experienced >/=1 defined breakthrough cardiac a
289 Twenty-
three patients experienced graft failure, and 70 patients (7%)
290 One cyclosporine-
treated patient experienced acute rejection between year 2 and y
291 zole efficacy was good, but 19 of 48
treated patients experienced side effects.
292 Belimumab-
treated patients experienced significant decreases in the number
293 Ambulation-evaluable eteplirsen-
treated patients experienced a 67.3 m benefit compared to placeb
294 Two patients experienced DLTs (one each in the 80 mg and 600
295 Two patients experienced transient grade 3 and 4 transaminas
296 Six patients experienced grade 2 RP, and
two patients experienced grade 3 RP; all recovered after cor
297 No isolated CNS relapse occurred, but
two patients experienced combined CNS relapses.
298 ion, and bleeding were also similar, but
WRF patients experienced a higher incidence of vascular deat
299 Younger patients experienced greater benefit from recent oncolog
300 tive to patients of middle age, the
youngest patients experienced 19% (95% CI, 7% to 33%) increased r